BRPI0812504A2 - Composto, composição farmacêutica e método de profilaxia ou tratamento de doença ou condição associados a receptor de canabinoides em sujeito mamífero - Google Patents
Composto, composição farmacêutica e método de profilaxia ou tratamento de doença ou condição associados a receptor de canabinoides em sujeito mamíferoInfo
- Publication number
- BRPI0812504A2 BRPI0812504A2 BRPI0812504-0A BRPI0812504A BRPI0812504A2 BR PI0812504 A2 BRPI0812504 A2 BR PI0812504A2 BR PI0812504 A BRPI0812504 A BR PI0812504A BR PI0812504 A2 BRPI0812504 A2 BR PI0812504A2
- Authority
- BR
- Brazil
- Prior art keywords
- prophylaxis
- compound
- treatment
- condition
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93675407P | 2007-06-21 | 2007-06-21 | |
| US60/936,754 | 2007-06-21 | ||
| US99442207P | 2007-09-19 | 2007-09-19 | |
| US60/994,422 | 2007-09-19 | ||
| US839507P | 2007-12-19 | 2007-12-19 | |
| US61/008,395 | 2007-12-19 | ||
| PCT/US2008/067632 WO2008157751A2 (en) | 2007-06-21 | 2008-06-20 | Substituted imidazoheterocycles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0812504A2 true BRPI0812504A2 (pt) | 2015-06-16 |
| BRPI0812504B1 BRPI0812504B1 (pt) | 2019-12-03 |
| BRPI0812504B8 BRPI0812504B8 (pt) | 2021-05-25 |
Family
ID=40137137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0812504A BRPI0812504B8 (pt) | 2007-06-21 | 2008-06-20 | composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7517874B2 (pt) |
| EP (1) | EP2170350B1 (pt) |
| JP (1) | JP5485148B2 (pt) |
| KR (1) | KR101605210B1 (pt) |
| CN (1) | CN101686989B (pt) |
| AU (1) | AU2008265655B2 (pt) |
| BR (1) | BRPI0812504B8 (pt) |
| CA (1) | CA2691776C (pt) |
| EA (1) | EA201000046A1 (pt) |
| ES (1) | ES2439255T3 (pt) |
| IL (1) | IL202616A0 (pt) |
| MY (1) | MY146924A (pt) |
| NZ (1) | NZ582760A (pt) |
| WO (1) | WO2008157751A2 (pt) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| JP4681231B2 (ja) | 2002-03-20 | 2011-05-11 | マンカインド コーポレイション | 吸入装置 |
| ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| MX373000B (es) | 2005-09-14 | 2020-05-21 | Mannkind Corp | Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas. |
| CN104383546B (zh) | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| EA201000046A1 (ru) * | 2007-06-21 | 2011-02-28 | Кара Терапеутикс, Инк. | Замещенные имидазогетероциклы |
| US8859538B2 (en) * | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| US20090062253A1 (en) * | 2007-08-31 | 2009-03-05 | Kalypsys, Inc. | Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease |
| CN101468988A (zh) * | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| MY155524A (en) | 2008-06-13 | 2015-10-30 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| EP2609954B1 (en) | 2008-06-20 | 2021-12-29 | MannKind Corporation | An interactive apparatus for real-time profiling of inhalation efforts |
| TWI494123B (zh) | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| TW201030007A (en) * | 2009-02-06 | 2010-08-16 | Gruenenthal Gmbh | Substituted spiro-amides as b1r modulators |
| TW201035102A (en) * | 2009-03-04 | 2010-10-01 | Gruenethal Gmbh | Sulfonylated tetrahydroazolopyrazines and their use as medicinal products |
| US8538707B2 (en) | 2009-03-11 | 2013-09-17 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| CN101899048B (zh) * | 2009-05-27 | 2013-04-17 | 上海恒瑞医药有限公司 | (R)-7-[3-氨基-4-(2,4,5-三氟-苯基)-丁酰]-3-三氟甲基-5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸甲酯的盐 |
| AU2010259943C1 (en) | 2009-06-12 | 2016-03-03 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| US8299103B2 (en) * | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| EP2470508A1 (en) | 2009-08-28 | 2012-07-04 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| JP5784622B2 (ja) | 2009-11-03 | 2015-09-24 | マンカインド コーポレ−ション | 吸入活動をシミュレートするための装置及び方法 |
| CA2793313C (en) | 2010-04-02 | 2018-01-23 | Euroscreen Sa | Nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
| US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
| RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
| CN102464661B (zh) * | 2010-11-16 | 2015-04-01 | 天津药明康德新药开发有限公司 | 一种5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸乙酯的制备方法 |
| HU1000676D0 (en) * | 2010-12-17 | 2011-02-28 | Pharmahungary 2000 Kft | Inhibitors of matrix metalloproteinase, pharmaceutical compositions thereof and use of them for preventing and treating diseases where the activation of mmp is involved |
| US9597340B2 (en) | 2011-02-25 | 2017-03-21 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| MX392150B (es) | 2011-02-25 | 2025-03-21 | Arena Pharm Inc | Moduladores de receptores canabinoides. |
| JP5945554B2 (ja) | 2011-02-25 | 2016-07-05 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター） |
| MX353285B (es) | 2011-04-01 | 2018-01-05 | Mannkind Corp | Paquete de blister para cartuchos farmaceuticos. |
| US20120309796A1 (en) | 2011-06-06 | 2012-12-06 | Fariborz Firooznia | Benzocycloheptene acetic acids |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| CA2849751C (en) | 2011-10-03 | 2019-06-11 | Euroscreen Sa | Chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof |
| HK1201475A1 (en) | 2011-10-24 | 2015-09-04 | Mannkind Corporation | Methods and compositions for treating pain |
| AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
| WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
| MX364895B (es) | 2013-03-13 | 2019-05-10 | Forma Therapeutics Inc | Nuevos compuestos y composiciones para la inhibicion de fasn. |
| BR112015023168B1 (pt) | 2013-03-15 | 2021-08-10 | Mannkind Corporation | Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina |
| BR122019026637B1 (pt) | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
| CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
| EP3083628B1 (en) * | 2013-12-20 | 2019-08-07 | Esteve Pharmaceuticals, S.A. | Fused imidazolyl derivatives, their preparation and use as medicaments |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| TW201837026A (zh) | 2017-01-10 | 2018-10-16 | 德商拜耳廠股份有限公司 | 作為除害劑之雜環衍生物（二） |
| KR102515694B1 (ko) | 2017-01-10 | 2023-03-29 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로사이클 유도체 |
| US20200078358A1 (en) | 2017-05-08 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds and Methods for Treatment of Visceral Pain |
| US20200140444A1 (en) * | 2017-07-24 | 2020-05-07 | Isocure Biosciences Inc. | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof |
| KR20200032702A (ko) * | 2017-07-27 | 2020-03-26 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피페라진 헤테로아릴 유도체, 그 제조 방법 및 의약에서 이의 용도 |
| CA3095367A1 (en) * | 2018-03-29 | 2019-10-03 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
| WO2020139988A1 (en) * | 2018-12-28 | 2020-07-02 | Forma Therapeutics, Inc. | Compositions for inhibiting ubiquitin specific protease 1 |
| CN111484497B (zh) * | 2019-01-25 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法 |
| MX2021008929A (es) * | 2019-01-25 | 2021-08-24 | Jiangsu Hengrui Medicine Co | Forma cristalina de un derivado de 1,2,3-triazolo[1,5-a]pirazinas, y metodo de preparacion para la forma de cristal. |
| CN111484498B (zh) * | 2019-01-25 | 2021-05-14 | 江苏恒瑞医药股份有限公司 | 咪唑并[1,5-a]吡嗪类化合物的晶型及其制备方法 |
| CN110563731A (zh) * | 2019-07-23 | 2019-12-13 | 上海药明康德新药开发有限公司 | 8-叔丁基-1-乙基-6,7-二氢-5H-咪唑并[1,5-a][1,4]二氮杂卓-1,8(9H)-二甲酸基酯制法 |
| CN114761408B (zh) * | 2019-12-19 | 2023-09-15 | 贝达药业股份有限公司 | Kras g12c抑制剂及其在医药上的应用 |
| IL297963A (en) | 2020-05-07 | 2023-01-01 | Adorx Therapeutics Ltd | Antagonists of the adenosine a2a receptor |
| KR20230080441A (ko) * | 2020-10-02 | 2023-06-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 전사 활성화 단백질의 이미다조피페라진 억제제 |
| JP7777131B2 (ja) | 2020-10-02 | 2025-11-27 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 転写活性化タンパク質のイミダゾピペラジン阻害剤 |
| WO2022166778A1 (zh) * | 2021-02-04 | 2022-08-11 | 江苏恒瑞医药股份有限公司 | 一种衣壳蛋白抑制剂的药物组合物及其制备方法 |
| JP7746406B2 (ja) * | 2021-04-21 | 2025-09-30 | 長春金賽薬業有限責任公司 | イミダゾール含有縮合環系誘導体、その調製方法及びその医薬上の応用 |
| JP2025522970A (ja) * | 2022-07-14 | 2025-07-17 | ザ スクリプス リサーチ インスティテュート | 肺疾患の治療のために２型肺胞細胞を増殖させる小分子調整剤 |
| EP4574826A4 (en) * | 2022-10-19 | 2025-12-10 | Changchun Genescience Pharmaceutical Co Ltd | CRYSTALLINE FORM OF AN NK3R ANTAGONIST, ITS PREPARATION PROCESS AND ITS USE |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2617478B1 (fr) | 1987-07-01 | 1990-01-05 | Esteve Labor Dr | Nouveaux derives d'aryl-heteroaryl cetones, leur procede de preparation ainsi que leur application a titre de medicament |
| JPH07101959A (ja) | 1993-09-30 | 1995-04-18 | Sankyo Co Ltd | １−メチルカルバペネム誘導体 |
| JPH07101957A (ja) | 1993-10-06 | 1995-04-18 | Asahi Glass Co Ltd | 環状プロスタグランジン誘導体およびその製造法 |
| US5753648A (en) | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| JPH08325234A (ja) | 1995-05-30 | 1996-12-10 | Yamanouchi Pharmaceut Co Ltd | 安息香酸誘導体又はその塩 |
| CA2432578C (en) | 2001-01-02 | 2008-04-01 | F. Hoffmann-La Roche Ag | Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists |
| US6960595B2 (en) | 2001-03-23 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | 5-6 to 5-7 Heterobicycles as factor Xa inhibitors |
| HUP0401107A3 (en) * | 2001-08-09 | 2004-10-28 | Actelion Pharmaceuticals Ltd | Novel benzo-fused heterocycles, their use process for their preparation and pharmaceutical compositions containing them |
| JPWO2003068776A1 (ja) | 2002-02-15 | 2005-06-02 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体 |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| ES2270143T3 (es) | 2002-08-07 | 2007-04-01 | Novartis Ag | Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona. |
| SE0203070D0 (en) | 2002-10-16 | 2002-10-16 | Astrazeneca Ab | Novel compounds |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7232823B2 (en) * | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| EP1644343B1 (en) | 2003-07-02 | 2007-07-04 | F. Hoffmann-La Roche Ag | 5-substituted quinazolinone derivatives |
| US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| WO2005058823A1 (ja) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
| PT1697371E (pt) * | 2003-12-19 | 2007-08-03 | Bristol Myers Squibb Co | Heterocíclos azabicíclicos como moduladores do receptor de canabinóides |
| HRP20070241T3 (hr) * | 2003-12-19 | 2007-07-31 | Bristol-Myers Squibb Company | Azabiciklički heterocikli kao modulatori kanabinoid receptora |
| RU2266906C1 (ru) | 2004-04-29 | 2005-12-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека |
| DE102004021716A1 (de) * | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
| US20070043057A1 (en) | 2005-02-09 | 2007-02-22 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
| EP1642577A1 (en) | 2004-09-07 | 2006-04-05 | Laboratorios del Dr. Esteve S.A. | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of central neuropathic pain |
| AR051596A1 (es) * | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| US20060089378A1 (en) | 2004-10-27 | 2006-04-27 | Mingde Xia | Tetrahydro-pyridinyl pyrazole cannabinoid modulators |
| WO2006087147A2 (en) | 2005-02-15 | 2006-08-24 | Laboratorios Del Dr. Esteve, S.A. | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia |
| US7629342B2 (en) * | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
| RU2281947C1 (ru) | 2005-07-05 | 2006-08-20 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Аннелированные карбамоилазагетероциклы, фокусированная библиотека, фармацевтическая композиция и способ получения |
| TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| PL1999132T3 (pl) * | 2006-03-30 | 2012-12-31 | Irm Llc | Azolopirymidyny jako inhibitory aktywności Receptora Kannabinoidowego typu 1 |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| EP2019677B1 (en) | 2006-05-16 | 2013-08-14 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| WO2007139992A2 (en) | 2006-05-26 | 2007-12-06 | Novartis Ag | ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS |
| US20100256357A1 (en) | 2006-08-09 | 2010-10-07 | Agouron Pharmaceuticals, Inc. | Heterocycles useful as inhibitors of carbonic anhydrase |
| EA201000046A1 (ru) * | 2007-06-21 | 2011-02-28 | Кара Терапеутикс, Инк. | Замещенные имидазогетероциклы |
| CN101468988A (zh) * | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
-
2008
- 2008-06-20 EA EA201000046A patent/EA201000046A1/ru unknown
- 2008-06-20 NZ NZ582760A patent/NZ582760A/en unknown
- 2008-06-20 AU AU2008265655A patent/AU2008265655B2/en not_active Ceased
- 2008-06-20 CA CA2691776A patent/CA2691776C/en active Active
- 2008-06-20 EP EP08771568.6A patent/EP2170350B1/en not_active Not-in-force
- 2008-06-20 CN CN200880020469.4A patent/CN101686989B/zh not_active Expired - Fee Related
- 2008-06-20 ES ES08771568.6T patent/ES2439255T3/es active Active
- 2008-06-20 MY MYPI20095453A patent/MY146924A/en unknown
- 2008-06-20 BR BRPI0812504A patent/BRPI0812504B8/pt not_active IP Right Cessation
- 2008-06-20 KR KR1020107001219A patent/KR101605210B1/ko active Active
- 2008-06-20 US US12/142,846 patent/US7517874B2/en active Active
- 2008-06-20 WO PCT/US2008/067632 patent/WO2008157751A2/en not_active Ceased
- 2008-06-20 JP JP2010513438A patent/JP5485148B2/ja active Active
- 2008-12-18 US US12/337,683 patent/US8431565B2/en active Active
-
2009
- 2009-12-09 IL IL202616A patent/IL202616A0/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2691776C (en) | 2016-05-10 |
| US7517874B2 (en) | 2009-04-14 |
| EP2170350A2 (en) | 2010-04-07 |
| ES2439255T3 (es) | 2014-01-22 |
| BRPI0812504B8 (pt) | 2021-05-25 |
| EP2170350B1 (en) | 2013-09-11 |
| US8431565B2 (en) | 2013-04-30 |
| CA2691776A1 (en) | 2008-12-24 |
| KR20100050459A (ko) | 2010-05-13 |
| NZ582760A (en) | 2011-12-22 |
| MY146924A (en) | 2012-10-15 |
| IL202616A0 (en) | 2010-06-30 |
| KR101605210B1 (ko) | 2016-03-21 |
| JP2010530891A (ja) | 2010-09-16 |
| EA201000046A1 (ru) | 2011-02-28 |
| AU2008265655B2 (en) | 2014-02-06 |
| JP5485148B2 (ja) | 2014-05-07 |
| EP2170350A4 (en) | 2011-09-28 |
| WO2008157751A3 (en) | 2009-03-12 |
| WO2008157751A2 (en) | 2008-12-24 |
| US20080318935A1 (en) | 2008-12-25 |
| CN101686989A (zh) | 2010-03-31 |
| CN101686989B (zh) | 2016-10-19 |
| AU2008265655A1 (en) | 2008-12-24 |
| BRPI0812504B1 (pt) | 2019-12-03 |
| US20090149450A1 (en) | 2009-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1009381A2 (pt) | compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica | |
| BRPI1004899A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac | |
| BRPI0921924A2 (pt) | composto, composição farmacêutica, uso de uma composição farmacêutica, e de um composto, e, método de tratamento de uma doença ou distúrbio mediado pelo receptor m1 muscarínico | |
| HUE050319T2 (hu) | Kompozíciók és eljárások alkoholfogyasztással kapcsolatos rendellenességek, fájdalom és más betegségek kezelésére | |
| BRPI0915267A2 (pt) | Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição | |
| IT1392423B1 (it) | Struttura di guanto, in particolare da motociclismo, e metodo per la sua realizzazione. | |
| BRPI0921317A2 (pt) | composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero | |
| BRPI0717753A2 (pt) | Método de tratamento ou redução do risco de uma doença causada por protozoários, e, composição. | |
| BRPI0817664A2 (pt) | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo | |
| BRPI0909180A2 (pt) | composição farmacêutica, e, método de tratamento de uma doença autoimune | |
| BRPI0914902A2 (pt) | composição farmacêutica e método para tratamento de mal de parkinson | |
| BRPI0909048A2 (pt) | composição farmacêutica, e, método de tratamento de uma doença autoimune | |
| BRPI0909179A2 (pt) | Composição farmacêutica, e, método de tratamento de uma doença autoimune. | |
| BRPI0821168A2 (pt) | anticorpo, hibridoma, e, métodos para tratar doenças em um paciente e para tratar um paciente de transplante | |
| BRPI0907162A2 (pt) | Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero | |
| BRPI0812851A2 (pt) | Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto | |
| BRPI0813580A2 (pt) | Antagonistas de receptor 1 de hormônio de concentração de melanina não básicos e métodos | |
| BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
| BRPI0905388A2 (pt) | "composição farmacêutica; compostos e métodos de tratamento de infecção por arenavirus" | |
| BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
| BRPI1013984A2 (pt) | composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto. | |
| BRPI0813001A2 (pt) | composto, método de tratamento ou profilaxia de dor neuropática e composição farmacêutica | |
| BRPI0718041A2 (pt) | Antagonista do receptor da angiotensina ii para prevenção ou tratamento de doenças sistêmicas em gatos | |
| EP2136814A4 (en) | MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE | |
| BRPI0919231A2 (pt) | agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: CARA THERAPEUTICS, INC. (US) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25G | Requested change of headquarter approved |
Owner name: CARA THERAPEUTICS, INC. (US) |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |